Log in

CVE:VPTVentriPoint Diagnostics Stock Price, Forecast & News

C$0.08
0.00 (0.00 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
C$0.08
Now: C$0.08
C$0.08
50-Day Range
C$0.08
MA: C$0.08
C$0.10
52-Week Range
C$0.07
Now: C$0.08
C$0.20
VolumeN/A
Average Volume182,396 shs
Market CapitalizationC$5.58 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease primarily in Canada, the Unites States, and China. The company offers Ventripoint Medical System, medical imaging system that is used to generate three-dimensional models with critical volume and functional measurements of a patient's heart chambers. It also provides a suite of applications for various heart diseases and imaging modalities, including congenital heart diseases, left or right heart failure, and normal hearts. The company was incorporated in 2005 and is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone416-848-4156

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$81,023.00
Cash FlowC$0.00 per share
Book ValueC($0.04) per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$5.58 million
Next Earnings DateN/A
OptionableNot Optionable

Receive VPT News and Ratings via Email

Sign-up to receive the latest news and ratings for VPT and its competitors with MarketBeat's FREE daily newsletter.

VentriPoint Diagnostics (CVE:VPT) Frequently Asked Questions

Has VentriPoint Diagnostics been receiving favorable news coverage?

Media stories about VPT stock have been trending somewhat positive recently, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. VentriPoint Diagnostics earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutVentriPoint Diagnostics.

Who are some of VentriPoint Diagnostics' key competitors?

What other stocks do shareholders of VentriPoint Diagnostics own?

Who are VentriPoint Diagnostics' key executives?

VentriPoint Diagnostics' management team includes the following people:
  • Dr. George Adams, CEO & Director (Age 68)
  • Mr. Desmond Hirson, Pres
  • Ms. Ellen Briant, CFO & Corp. Sec.
  • Dr. Alvira Macanovic Ph.D., VP of Devel. & Operations
  • Ms. Jessica Naman, Marketing Mang.

What is VentriPoint Diagnostics' stock symbol?

VentriPoint Diagnostics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "VPT."

How do I buy shares of VentriPoint Diagnostics?

Shares of VPT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is VentriPoint Diagnostics' stock price today?

One share of VPT stock can currently be purchased for approximately C$0.08.

How big of a company is VentriPoint Diagnostics?

VentriPoint Diagnostics has a market capitalization of C$5.58 million and generates C$81,023.00 in revenue each year.

What is VentriPoint Diagnostics' official website?

The official website for VentriPoint Diagnostics is www.ventripoint.com.

How can I contact VentriPoint Diagnostics?

The company can be reached via phone at 416-848-4156.

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.